The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Biosample Use Program, 2020Relationship of Plasma Vitamin B12 and Homocysteine Levels with Outcomes in SURE-PD and STEADY-PD Trials
Study Rationale:
Vitamin B12 levels are lower in people with Parkinson’s disease. Our prior investigation showed that lower B12 levels were associated with more rapid worsening of gait and stability... -
Biosample Use Program, 2020Metabolomic Analysis of Penetrance, Prognosis and Tracking Biomarkers of LRRK2 PD
Study Rationale:
Mutations in a gene called LRRK2 can cause Parkinson's disease but only a quarter to half of the people who carry one of these mutations will actually develop Parkinson’s in their... -
Research Grant, 2020More Than Pretty Pictures: Ion Imaging of Lipid Content and Flux Kinetics in Models of Parkinson’s Disease
Study Rationale:
Glycosphingolipids are natural cellular fats. They are components of cellular membranes that fulfill multiple functional roles, from cell structure and transport to signaling. The... -
Therapeutic Pipeline Program, 2020Developing TMEM175 Activators as Therapeutics for Parkinson's Disease
Study Rationale:
Our aim is to develop a drug that will slow or stop the progression of Parkinson’s disease in patients who carry a mutation in the TMEM175 gene. The TMEM175 gene produces a... -
Research Grant, 2020Parkinson’s Disease with Mild Cognitive Impairment Treated with a Nicotinic Agonist Drug
Study Rationale:
Parkinson’s disease with mild cognitive impairment (PD-MCI) is common, has important clinical consequences, and there is currently no treatment available. The underlying pathology of... -
Therapeutic Pipeline Program, 2020Identification and Characterization of Small Molecule Activators of ATP13A2 for Parkinson’s Disease Therapy
Study Rationale:
In Parkinson’s disease, neurons degenerate because of a disturbed function of the lysosomes and mitochondria. The lysosomal transporter ATP13A2 (PARK9) is genetically implicated in...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.